Tuanyëcuäny de cuäŋ ee tuanytuɛnytuɛɛny ye lac yök në röör yiic, ku ye rot lac looi në röör dït.
Cït mɛn cï ye lueel në akutnhom de American Cancer Society, tuaany de prostate ee tuaany de rou ye lac yök në röör ke America yiic, cï të cenë tuany de cuäŋ rot bɛ̈n juak thïn.
Pan de United States, ke raan tök në röör kaa 9 abï tuany de prostate cancer ya yök në pïïrden yic.
Në ruöön de 2021, ke ka cï kek thɔ̈ɔ̈ŋ ke kɔc ke 248,530 abë kek tuany në tuany de prostate cancer ya yök ku kɔc ke 34,130 abë kek thou në tuany kënë yic.
Ku na yïn ya, ke ka thiekic ba nyic ke tuany de prostate cancer ee lac tɔ̈ɔ̈c, ku ka ye lac pïïr të cenë ye yök ke cï lac tuany.
Fesinmeyer MD, Gulati R, Zeliadt S, Weiss N, Kristal AR, Etzioni R: Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiol Biomarkers Prev. 2009, 18 (3): 808-15.
Peng P, Gong YM, Bao PP, Ke JZ, Xiang YM, Zhang ML, Zheng Y: [Estimates and prediction of prostate cancer incidence, mortality and prevalence in China, 2008]. Zhonghua Liu Xing Bing Xue Za Zhi. 2012, 33 (10): 1056-9.
Delongchamps NB, Singh A, Haas GP: The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006, 13 (3): 158-68.
Li J, German R, King J, Joseph D, Thompson T, Wu XC, Ajani U, Tai E: Recent trends in prostate cancer testing and incidence among men under age of 50. Cancer Epidemiol. 2012, 36 (2): 122-7.
Yu XQ, Luo Q, Smith DP, Clements MS, O'Connell DL: Prostate cancer prevalence in New South Wales Australia: a population-based study. Cancer Epidemiol. 2015, 39 (1): 29-36.
Ondrusova M, Mrozova L, Ondrus D, Mrinakova B: Trends and estimates in prostate cancer incidence, mortality and prevalence in the Slovak Republic, 1968-2012. Neoplasma. 2013, 60 (4): 446-51.
['Wɛ̈t cï lueel: wal']
['Wɛbthait kën ee piööc ku wël tɔ̈u thïn ku acie kë ye looi bï kɔc ke akïm ya lɛ̈k wala bï kɔc ke luɔi ya kony.']
['Wël cï kek ya lueel në ye athöör kënë yic acïï lëu bï kek ya kony agonë tuanytuɛny ya ŋic ku bï kek ya kony, ku kɔc wïc kuɔɔny de akïm adhil akïm de akïm ya thiëëc bï kek ya kony.']
['Tiɛ̈ŋë kä ye kuɔɔny de neural net looi, man ye kä ye bɛ̈n në kä cï kek ya thiëëc yiic, aye kek cɔk tɔ̈ ëke cïï kek ye deet yiic në thɛɛr juëc yiic. Cïmën de, ciin de kɔc cï kek yök ëke tuany.']
['Thïëc wɛ̈t akïmdu ka raan dɛ̈t wënë cï piöc ë pialgup wënë cï yök në biäk de tuaany. Duk wɛ̈t akïm ye kuɛ̈ɛ̈c nhom cɔk alɔn cï yen ya kë cï kueen në wɛbthait kënnë yic. Na ye tak ke yïn nɔŋ kë wïc bë yï kony në tuany, cɔl 911 ka lɔɔr në ɣön akïm tɔ̈u të thiääk ke yï në kaam thiin koor yic. Acïn akïm-tuany ye thiääk në yen në wɛbthait kënnë yic ka luɔ̈i de. BioMedLib ka kɔc cï luöi, ka raan ëbɛ̈n ye luui në yen në wɛbthait kënnë yic, acïn kë ye lueel, ye lueel ka ye lueel, në kë de wël cï kek gɔ̈ɔ̈r në ye athöör kënnë yic ka luɔ̈i de.']
['Wɛ̈t cï lueel: copyright']
['Lööŋ ke Digital Millennium Copyright Act de 1998, 17 U.S.C. § 512 (ye DMCA) ee kɔc ye käke kɔc gɔ̈t gam ke kä tɔ̈ në Internet aye käken tɔ̈ në U.S. copyright law dhoŋ kɔ̈th. ']
['Na ye gam në yith ke këriɛ̈ɛ̈c ka kä cï gɔ̈ɔ̈r tɔ̈ në wɛbthaitda ka kuɔɔnyda yic acï löŋ de gël de kä cï gɔ̈ɔ̈r dhoŋ kɔ̈u, ke yïn (ka raan ye yïn luɔ̈ɔ̈i) alëu ba ɣok tuɔ̈c wɛ̈t bï këriɛ̈ɛ̈c ka kä cï gɔ̈ɔ̈r nyaai, ka bï yïn pëën ba lɔ thïn. ']
["Wël aa bë ke tuɔɔc në athöör yic në email (tïŋ 'Rin de athöör' në biäk de email)."]
['DMCA ee wïc lɔnadɛ̈ ke kë ca lueel de kä cï keek gɔ̈ɔ̈r cï keek luɔ̈ɔ̈i anɔŋic wël cï keek gɔ̈ɔ̈r: (1) luɛɛl de kä cï keek luɔ̈ɔ̈i cï keek gɔ̈ɔ̈r cï keek luɔ̈ɔ̈i cï keek lueel; (2) luɛɛl de kä cï keek gɔ̈ɔ̈r cï keek lueel ku wël cï keek lueel bï keek cɔk lëu bïkë kä cï keek gɔ̈ɔ̈r yök; (3) wël bï yïn ke kɔn ya kɔɔr, nɔŋiic adrɛ̈ɛ̈rdu, namba de telepun ku adrɛ̈ɛ̈r de imeel; (4) wɛ̈t cï lueel në yï nhom lɔnadɛ̈ ke yïn ye gam ke kë cï gɔ̈ɔ̈r cï looi në kueer cï yïn ye gaam acie gam në raan de kä cï keek gɔ̈ɔ̈r cï keek luɔ̈ɔ̈i, ka raan de lööŋ, ka në luɔɔi de löŋ; ']
['(5) athöör cï yïn gätpiny në awuɔ̈c de wɛ̈t lueth, lɔnadɛ̈ ke wël tɔ̈ në athöör yic aye yith ku lɔnadɛ̈ ke yïn anɔŋ riɛl ba kä cï gɔ̈t ke lööŋ ke raan nɔŋ nhïïm ya looi në kë cï wuɔ̈ɔ̈c; ']
['Ku (6) ke ye kä cï gɔ̈t ke guɔ̈p ka kä cï gɔ̈t ke mɛ̈ɛ̈t de raan de kä cï luɔ̈ɔ̈i ka raan cï gäm riɛl bï luui në nyin de raan de kä cï luɔ̈ɔ̈i. ']
['Na këc wël cï gɔ̈ɔ̈r nhial tɔ̈u thïn kedhiɛ gɔ̈t, ke ka lëu bï këdun cï yïn gaam ya gääu.']
['Thiëc kek']
['Tuɔɔc email tënë ɣok na nɔŋ këdun thiëc/cï yïn tak.']
How common is prostate cancer?
Prostate cancer is one of the most common types of cancer in men, particularly in older men.
According to the American Cancer Society, prostate cancer is the second most common cancer in American men, behind skin cancer.
In the United States, about 1 in 9 men will be diagnosed with prostate cancer during their lifetime.
In 2021, it is estimated that there will be about 248,530 new cases of prostate cancer and about 34,130 deaths from prostate cancer.
However, it is important to note that prostate cancer is highly treatable, and the survival rate is high when it is detected early.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Në kë de']
['BioMedLib ee kɔmbiötar ke rɔt looi (algorithms ke adit) luɔ̈ɔ̈i bï kä ye thiëëc ku kä ye bɛ̈ɛ̈r ya looi.']
['Ɣok aye gɔ̈t në biomedical 35 million në PubMed/Medline. Ku në webpages de RefinedWeb.']
